MedTrace Logo

Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

NCT06029465 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-09-08

No results posted yet for this study

Summary

The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.

Conditions

  • Rhabdomyosarcoma

Sponsors & Collaborators

  • Power Life Sciences Inc.

    lead INDUSTRY

Principal Investigators

  • Michael B Gill · Power Life Sciences Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2025-10-31
Completion
2026-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029465 on ClinicalTrials.gov